Epilepsy Stocks
Biopharmaceutical and medical technology firms in this sector focus on modulating neuronal excitability through ion channel regulation, synaptic protein targeting, and neuromodulation hardware. Revenue models depend on navigating complex regulatory pathways for orphan drug designations and overcoming high clinical failure rates associated with central nervous system disorders.
As of Oct 23, 2026, Epilepsy has 13 US-listed companies worth $35.9B combined. The median member moved +3.6% over the past week; BHVN led at +28.8% and FLNA trailed at -9.7%.
Companies in Epilepsy
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- LIVN – LivaNova PLC, $4.3B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- BHVN – Biohaven Ltd., $1.8B
- STOK – Stoke Therapeutics Inc, $1.7B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- CBLL – CeriBell, Inc, $888M
- DRUG – Bright Minds Biosciences Inc, $506M
- OVID – Ovid Therapeutics Inc, $441M
- NPCE – Neuropace Inc, $435M
- FLNA – Filana Therapeutics, Inc., $34M
- NMTC – Neuroone Medical Technologies Corp, $9.7M